Complete pathologic response after two-stage cytoreductive surgery with HIPEC for bulky pseudomyxoma peritonei: proof of concept

References

• Mittal R, Chandramohan A, Moran B. Pseudomyxoma peritonei: natural history and treatment. Int J Hyperthermia. 2017;33(5):511–519.
   PubMed Web of Science ®Google Scholar
• Delhorme J-B, French National Network of Peritoneal Surface Malignancies (RENAPE), Severac F, Averous G, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendicular and extra-appendicular origin. Br J Surg. 2018;105(6):668–676.
   PubMed Web of Science ®Google Scholar
• Chua TC, Yan TD, Smigielski ME, et al. Long-term survival in patients with pseudomyxoma peritonei treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy: 10 years of experience from a single institution. Ann Surg Oncol. 2009;16(7):1903–1911.
   PubMed Web of Science ®Google Scholar
• Chua TC, Al-Zahrani A, Saxena A, et al. Secondary cytoreduction and perioperative intraperitoneal chemotherapy after initial debulking of pseudomyxoma peritonei: a study of timing and the impact of malignant dedifferentiation. J Am Coll Surg. 2010;211(4):526–535.
   PubMed Web of Science ®Google Scholar
• Carr NJ, Peritoneal Surface Oncology Group International, Cecil TD, Mohamed F, et al. A consensus for classification and pathologic reporting of Pseudomyxoma Peritonei and associated appendiceal neoplasia: the results of the Peritoneal Surface Oncology Group International (PSOGI) modified Delphi process. Am J Surg Pathol. 2016;40(1):14–26.
   PubMed Web of Science ®Google Scholar
• Andréasson H, Graf W, Nygren P, et al. Outcome differences between debulking surgery and cytoreductive surgery in patients with pseudomyxoma peritonei. Eur J Surg Oncol. 2012;38(10):962–968.
   PubMed Web of Science ®Google Scholar
• Benhaim L, Faron M, Gelli M, et al. Survival after complete cytoreductive surgery and HIPEC for extensive pseudomyxoma peritonei. Surg Oncol. 2019;29:78–83.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother. Pharmacol. 1999;43(7):S15–S25.
   PubMed Web of Science ®Google Scholar
• Goéré D, Souadka A, Faron M, et al. Extent of colorectal peritoneal carcinomatosis: attempt to define a threshold above which HIPEC does not offer survival benefit: a comparative study. Ann Surg Oncol. 2015;22(9):2958–2964.
   PubMed Web of Science ®Google Scholar
• Bakrin N, FROGHI (FRench Oncologic and Gynecologic HIPEC) Group, Bereder JM, Decullier E, et al. Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients. Eur J Surg Oncol. 2013;39(12):1435–1443.
   PubMed Web of Science ®Google Scholar
• Villeneuve L, RENAPE Network, Passot G, Glehen O, et al. The RENAPE observational registry: rationale and framework of the rare peritoneal tumors French patient registry. Orphanet J Rare Dis. 2017;12(1):37.
   PubMed Web of Science ®Google Scholar
• Dindo D, Demartines N, Clavien P-A. Classification of surgical complications. Ann Surg. 2004;240(2):205–213.
   PubMed Web of Science ®Google Scholar
• Moran B, Baratti D, Yan TD, et al. Consensus statement on the loco-regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei). J Surg Oncol. 2008;98(4):277–282.
   PubMed Web of Science ®Google Scholar
• Saxena A, Yan TD, Chua TC, et al. Critical assessment of risk factors for complications after cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol. 2010;17(5):1291–1301.
   PubMed Web of Science ®Google Scholar
• Benhaim L, Honoré C, Goéré D, et al. Huge pseudomyxoma peritonei: surgical strategies and procedures to employ to optimize the rate of complete cytoreductive surgery. Eur J Surg Oncol. 2016;42(4):552–557.
   PubMed Web of Science ®Google Scholar
• Ceelen WP, Flessner MF. Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence. Nat Rev Clin Oncol. 2010;7(2):108–115.
   PubMed Web of Science ®Google Scholar
• De Simone M, Scuderi S, Vaira M, et al. Treatment of pseudomyxoma peritonei with two times- cytoreduction and hypertermic antiblastic peritoneal perfusion (HAPP). J Exp Clin Cancer Res. 2003;22(4 suppl):25–28.
   PubMed Web of Science ®Google Scholar
• McBride K, McFadden D, Osler T. Improved survival of patients with pseudomyxoma peritonei receiving intraperitoneal chemotherapy with cytoreductive surgery: a systematic review and meta-analysis. J Surg Res. 2013;183(1):246–252.
   PubMed Web of Science ®Google Scholar
• Bjersand K, Mahteme H, Sundström Poromaa I, et al. Drug sensitivity testing in cytoreductive surgery and intraperitoneal chemotherapy of pseudomyxoma peritonei. Ann Surg Oncol. 2015;22(S3):810–816.
   Web of Science ®Google Scholar
• Stewart JH, Shen P, Russell G, et al. A phase I trial of oxaliplatin for intraperitoneal hyperthermic chemoperfusion for the treatment of peritoneal surface dissemination from colorectal and appendiceal cancers. Ann Surg Oncol. 2008;15(8): 2137–2145.
   PubMed Web of Science ®Google Scholar
• Elias D, Bonnay M, Puizillou JM, et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol. 2002;13(2):267–272.
   PubMed Web of Science ®Google Scholar
• Wisselink DD, Braakhuis LLF, Gallo G, et al. Systematic review of published literature on oxaliplatin and mitomycin C as chemotherapeutic agents for hyperthermic intraperitoneal chemotherapy in patients with peritoneal metastases from colorectal cancer. Crit Rev Oncol Hematol. 2019;142:119–129.
   PubMed Web of Science ®Google Scholar
• Duron J-J. Postoperative intraperitoneal adhesion pathophysiology. Colorect Dis. 2007;9(s2):14–24.
   PubMed Web of Science ®Google Scholar
• Gagnière J, Veziant J, Pereira B, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the elderly: is it reasonable? A meta-analysis. Ann Surg Oncol. 2018;25(3):709–719.
   PubMed Web of Science ®Google Scholar
• Solass W, Sempoux C, Carr NJ, et al. Reproducibility of the peritoneal regression grading score for assessment of response to therapy in peritoneal metastasis. Histopathology. 2019;74(7):1014–1024.
   PubMed Web of Science ®Google Scholar